Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
26 studies found for:    "gene therapy" OR "gene transfer" OR "virus delivery" | plasmid
Show Display Options
Rank Status Study
1 Completed The Effect of Mobilized Stem Cell by G-CSF and VEGF Gene Therapy in Patients With Stable Severe Angina Pectoris
Condition: Ischemic Heart Disease
Intervention: Genetic: VEGF-A165 plasmid
2 Completed Gene Therapy of Pancreatic Ductal Adenocarcinoma
Condition: Pancreatic Adenocarcinoma
Intervention: Genetic: Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes
3 Active, not recruiting IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer
Condition: Merkel Cell Carcinoma
Interventions: Biological: interleukin-12 gene;   Biological: electroporation-mediated plasmid DNA vaccine therapy
4 Completed Angiogenesis Using VEGF-A165/bFGF Plasmid Delivered Percutaneously in No-option CAD Patients; a Controlled Trial
Condition: Coronary Artery Disease
Intervention: Genetic: intramyocardial injection of VEGF-A165/bFGF:placebo plasmid
5 Terminated Gene Electrotransfer to Muscle With Plasmid AMEP in Patients With Disseminated Cancer
Condition: Metastatic Malignant Neoplasm
Intervention: Drug: Plasmid AMEP
6 Completed Trial of VLTS-589 in Subjects With Intermittent Claudication
Conditions: Intermittent Claudication;   Peripheral Vascular Disease
Intervention: Genetic: Plasmid based Gene Transfer product-VLTS-589
7 Not yet recruiting Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Peripheral Nerve Injury
Condition: Peripheral Nerve Injury
Intervention: Drug: Neovasculgen
8 Not yet recruiting Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon
Condition: Secondary Raynaud's Phenomenon
Intervention: Drug: Neovasculgen
9 Active, not recruiting Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC)
Condition: Head and Neck Squamous Cell Carcinoma
Interventions: Biological: Plasmid interleukin-12;   Device: Intratumoral electroporation
10 Active, not recruiting Trial of pIL-12 Electroporation Malignant Melanoma
Condition: Melanoma
Interventions: Biological: Plasmid INTERLEUKIN-12;   Device: Intratumoral Electroporation
11 Terminated Efficacy and Safety of AMG0001 in Subjects With Critical Limb Ischemia
Condition: Critical Limb Ischemia
Interventions: Genetic: HGF Plasmid (AMG0001);   Genetic: Matching Placebo
12 Completed Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia
Condition: Critical Limb Ischemia
Interventions: Genetic: Low Dose VM202;   Genetic: High Dose VM202;   Other: Placebo
13 Completed Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia
Conditions: Arterial Occlusive Disease;   Ulcers;   Ischemia;   Peripheral Vascular Disease
Interventions: Genetic: NL003;   Other: Normal Saline
14 Completed Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer
Condition: Head and Neck Cancer
Interventions: Biological: gene therapy;   Biological: interleukin-2 gene;   Drug: methotrexate
15 Not yet recruiting Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer
Condition: Pancreatic Adenocarcinoma
Interventions: Drug: Gene Therapy product CYL-02;   Drug: Gemcitabine
16 Completed Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma
Condition: Malignant Melanoma
Interventions: Genetic: IL-12pDNA;   Procedure: electroporation
17 Completed Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells
Conditions: Leukemia;   Leukemia, B-Cell, Chronic
Intervention: Biological: IL-2 AND HUMAN CD40 LIGAND PLASMID GENE MODIFIED AUTOLOGOUS TUMOR CELLS
18 Terminated A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients
Condition: Colorectal Cancer
Intervention: Drug: EGEN-001-301
19 Completed Single Dose of pGM169/GL67A in CF Patients
Condition: Cystic Fibrosis
Intervention: Drug: pGM169/GL67A
20 Active, not recruiting A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia
Conditions: Critical Limb Ischemia;   Vascular Diseases;   Peripheral Arterial Disease
Intervention: Genetic: HGF Plasmid

   Previous Page Studies Shown (1-20) Next Page (21-26) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.